Polycystic ovary syndrome (PCOS) represents a metabolic-reproductive disorder where GLP-1 RAs show therapeutic potential by addressing core pathophysiological mechanisms of insulin resistance and compensatory hyperinsulinemia that exacerbate ovarian androgen production [123,124]. The gene discussed is GLP1R; the disease is hyperinsulinism.